Penetration of orally administered prulifloxacin into human prostate tissue

Clinical Drug Investigation

Volumn 29, Issue 1, 2009, Pages 27-34

  Giberti, Claudio ^a   Gallo, Fabrizio ^a   Rosignoli, Maria T ^b   Ruggieri, Alessandro ^b   Barattè, Simona ^c   Picollo, Rossella ^b   Dionisio, Paolo ^b  

^a IRCCS Istituto Giannina Gaslini   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Benign prostatic hyperplasia; Prostate; Prostatitis; Prulifloxacin, pharmacokinetics

Indexed keywords

DRUG METABOLITE; PRULIFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TRANSURETHRAL RESECTION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; DIOXOLANES; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATITIS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 57449112834     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929010-00003     Document Type: Article

References (20)

1. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-34
2. Tougou K, Nakamura A, Watanabe S, et al. Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1997; 26: 355-9
3. Prats G, Roig C, Mirò E, et al. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21 (4): 328-34
4. Montanari MP, Mingoia M, Varaldo PE. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 2001; 45 (12): 3616-22
5. Gualco L, Schito AM, Schito GC, et al. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. Int J Antimicrob Agents 2007; 29 (6): 679-87
6. Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 2003; 53 (3): 201-5
7. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34: 930-7
8. Concia E, Allegranzi B, Ciottoli GB, et al. Penetration of orally administered prulifloxacin into human lung tissue. Clin Pharmacokinet 2005; 44 (12): 1287-94
9. Gorlero F, Lorenzi P, Rosignoli MT, et al. Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. Drugs R D 2007; 8 (6): 373-81
10. Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31 Suppl. 1: S85-90
11. Charalabopoulos K, Karachalios G, Baltogiannis D, et al. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003; 49 (6): 269-79
12. Naber KG. Management of bacterial prostatitis: what's new? BJU Int 2008; 101 Suppl. 3: 7-10
13. Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 2008; 8: 12
14. Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007; 178 (6): 2411-5
15. Png JC, Tan E, Foo KT, et al. A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Br J Urol 1997; 79 (5): 781-4
16. Kovarik JM, de Hond JA, Hoepelman IM, et al. Intraprostatic distribution of lomefloxacin following multiple-dose administration. Antimicrob Agents Chemother 1990; 34 (12): 2398-401
17. McNeal JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol 1972; 107 (6): 1008-16
18. Boerema JB, Dalhoff A, Debruyne FM. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985; 31 (1): 13-8
19. Giannarini G, Mogorovich A, Valent F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 2007; 19 (3): 304-8
20. Roveta S, Schito AM, Marchese A, et al. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 2005; 26 (5): 366-72